×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: blood | pressure | drug | prestalia

Combo Blood Pressure Treatment OKd by FDA

By    |   Tuesday, 27 January 2015 12:34 PM

A new combination pill to treat people with high blood pressure has won approval from the U.S. Food and Drug Administration.
 
Prestalia, which combines fixed doses of two high blood pressure drugs perindopril arginine and amlodipine besylate, is intended to be used in patients whose blood pressure is not adequately controlled by one medication. 

It is also approved as a first line therapy for patients who are likely to need multiple drugs to reach their blood pressure goals, the FDA said.
 
Perindopril arginine is an ACE inhibitor and amlodipine is a calcium channel blocker. Each type of drug works in different ways, but both widen blood vessels and improve blood flow, reducing the force of blood through the heart, thereby reducing blood pressure.
 
The FDA approval was based on data from the 837 patients enrolled in the PATH trial (Perindopril Amlodipine for the Treatment of Hypertension). The study demonstrated that the fixed-dose combination of both medications in a single pill controlled blood pressure than either medication alone.
 
“We now have another great combination of two drugs each with an evidence-based outcome history that are combined in a single pill,” said George Bakris, M.D., former president of the American Society of Hypertension and principal investigator for the PATH trial.
 
The drug manufacturer, Symplmed plans to make Prestalia available within the next few months.
 
 

© 2022 NewsmaxHealth. All rights reserved.


Health-News
A new combination pill to treat people with high blood pressure has won approval from the U.S. Food and Drug Administration. Prestalia, which combines fixed doses of two high blood pressure drugs perindopril arginine and amlodipine besylate, is intended to be used in...
blood, pressure, drug, prestalia
222
2015-34-27
Tuesday, 27 January 2015 12:34 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved